The FDA declared the shortage of Novo Nordisk's weight-loss drugs over, giving compounders until May to stop making alternatives. An industry group representing compounders is suing. Dr. Angela Fitch ...
While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...
NAION is a condition that causes sudden vision loss in one eye due to reduced blood flow to the optic nerve. The damaged ...
A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
WXMI Grand Rapids, MI on MSN23h
Skin Envy explains Semaglutide and Tirzepatide
None ...
For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...
“As time goes on, they’re more willing to share their story because they get so many compliments,” she said. “The person who is next to them says, ‘Tell me your secret,’ and they may whisper my name ...
Eli Lilly & Co. said Tuesday it's cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will also ...
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Coverage complications are not unusual in the U.S. healthcare system. But the challenge is magnified for these obesity ...